Toxicity of topical lidocaine applied to the breasts to reduce discomfort during screening mammography

Colleen K Lambertz, Christopher J Johnson, Paul G Montgomery, James R Maxwell, Stefanie J Fry, Colleen K Lambertz, Christopher J Johnson, Paul G Montgomery, James R Maxwell, Stefanie J Fry

Abstract

Background: We measured the effect of 30 milliliters (mL) of 4% lidocaine gel on the breasts and chest wall of healthy women covered for 1 h on plasma concentrations of lidocaine and its principal metabolite, monoethylglycinexylidide (MEGX), electrocardiogram (EKG) results, and adverse events.

Materials and methods: This institutional review board-approved, prospective, open-label study complied with the Health Insurance Portability and Accountability Act (HIPAA). The study evaluated 10 healthy women aged 42-75 years with 30 mL of 4% lidocaine gel on the skin of the breasts and chest wall covered for 1 h. Cardiac and neurological assessments were performed and blood was drawn for lidocaine and MEGX levels at baseline and 1/2, 1, 2, 3, 4, 6, and 8 h after application. EKGs were performed before application and at 3 h. Subjects provided informed written consent. Primary and secondary outcomes were plasma concentrations of lidocaine and MEGX and frequency of adverse events, respectively. Statistical analysis included paired t-tests for EKGs and repeated measures regression for vital signs.

Results: No lidocaine was detected in the blood of 9 of 10 subjects. One subject had low plasma concentrations of lidocaine just above the level of detection the first 4 h after application only. No MEGX was detected. Mean decrease in heart rate was likely multifactorial.

Conclusion: Thirty mL of 4% lidocaine gel on the breasts and chest wall covered for 1 h in healthy women resulted in plasma concentrations of lidocaine and MEGX well below therapeutic or toxic levels and no clinically significant adverse events.

Keywords: Breast; lidocaine; mammogram; pain; toxicity.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Schillinger JA, Mosbaek C, Austin D, Jack L, Jr, Heumann M, Moore J, et al. Health care reform in Oregon: The impact of the Oregon Health Plan on utilization of mammography. Am J Prev Med. 2000;18:11–17.
    1. Keefe FJ, Hauck ER, Egert J, Rimer B, Kornguth PJ. Mammography pain and discomfort: A cognitive-behavioral perspective. Pain. 1994;56:247–60.
    1. Rutter D, Calnan M, Vaile MS, Field S, Wade KA. Discomfort and pain during mammography: Description, prediction, and prevention. BMJ. 1992;305:443–5.
    1. Kornguth PJ, Keefe FJ, Conaway MR. Pain during mammography: Characteristics and relationship to demographic and medical variables. Pain. 1996;66:187–94.
    1. Nielsen BB, Miaskowski C, Dibble SL, Beber B, Altman N, McCoy CB. Pain and discomfort associated with film-screen mammography. J Natl Cancer Inst. 1991;83:1754–6.
    1. Mendelblatt J, Kanetsky PA. Effectiveness of interventions to enhance physician screening for breast cancer. J Fam Pract. 1995;40:162–71.
    1. Lambertz CK, Johnson CJ, Montgomery PG, Maxwell JR. Premedication to reduce discomfort during screening mammography. Radiology. 2008;248:765–72.
    1. U. S. Food and Drug Administration Center for Drug Evaluation and Research. FDA public health advisory: Life-threatening side effects with the use of skin products containing numbing ingredients for cosmetic procedures. 2007. Feb 9, [Last accessed on 2011 Aug 23]. Available from: .
    1. U.S. Food and Drug Administration Center for Drug Evaluation and Research. FDA public health advisory: Potential hazards of skin products containing numbing ingredients for relieving pain from mammography and other medical tests and conditions. 2009. Jan 16, [Last accessed on 2011 Aug 23]. Available from: .
    1. Marra D, Yip D, Fincher E, Moy R. Systemic toxicity from topically applied lidocaine in conjunction with fractional photothermolysis. Arch Dermatol. 2006;142:104–6.
    1. Brunton LL, Lazo JS, Parker KL, editors. 11th ed. New York: McGraw-Hill; 2006. Goodman and Gilman's the pharmacological basis of therapeutics.
    1. Jupiter, FL, USA: ESBA Laboratories Inc; [Last accessed on 2011 Aug 23]. TOPICAINE® Package insert. Available from: .
    1. Greenwood Village, Colo: Thomson Healthcare; [Last accessed on 2011 Aug 23]. Micromedex® Healthcare Series [intranet database].Version 5.1.
    1. Hidvegi N, Nduka C, Myers S, Dziewulski P. Estimation of breast burn size. Plast Reconstr Surg. 2004;113:1591–7.
    1. Mosteller R. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
    1. Brosh-Nissimov T, Ingbir M, Weintal I, Fried M, Porat R. Central nervous system toxicity following topical skin application of lidocaine. Eur J Clin Pharmacol. 2004;60:683–4.
    1. Antiarrhythmic Drugs. American Heart Association, Inc. 2009. [Last accessed on 2011 Aug 23]. Available from: .
    1. PLIAGLIS™ package insert. GALDERMA LABORATORIES, L.P., Fort Worth, TX. 2007
    1. EMLA® package insert. AstraZeneca LP, Wilmington, DE
    1. Nestor M. Safety of occluded 4% liposomal lidocaine cream. J Drugs Dermatol. 2006;5:618–20.
    1. Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5% Am J Health-Syst Pharm. 2002;59:2215–20.
    1. Campbell BJ, Rowbotham M, Davies PS, Jacob P., III Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002;91:1343–50.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren